Sorrento Taps China’s Mabtech For Biosimilars Deal
This article was originally published in PharmAsia News
Executive Summary
Sorrento Therapeutics has gained exclusive licensing rights from China’s Mabtech to develop four biosimilar and biobetter products for oncology and auto-immune diseases in western markets and Japan. China’s homegrown biopharmaceutical company has shown another example of its research capability to develop new drugs for the global market.